Autoimmune Myasthenia Gravis has a prevalence of approximately 14-40 per 100,000 individuals in the United States

Myasthenia Gravis (MG) is the prototype neuromuscular disease with the immunological pathogenesis. It is an acquired autoimmune disease affecting synaptic transmission via the neuromuscular junction mainly due to the presence of autoantibodies against the acetylcholine receptors (AChR) between the synaptic space of the skeletal muscles. It leads to an impairment of the neuromuscular transmission and corresponding clinical symptoms such as fluctuating muscle weakness and fatigability.

The disease can be managed effectively with therapies that include anticholinesterase agents, rapid immunomodulatory therapies, chronic immunosuppressive agents, and thymectomy. Treatment is individualized and depends upon the age of the patient; the severity of the disease, particularly dictated by respiratory or bulbar involvement; and the pace of progression. The goals of therapy in MG are to render patients minimally symptomatic or better while minimizing side effects from medications. MG is a chronic but treatable disease, and many patients can achieve sustained remission of symptoms and full functional capacity.

For detailed analysis of the TOC for the reports browse through: https://univdatos.com/report/global-myasthenia-gravis-pipeline--analysis-2019

Most patients need immunosuppression in addition to symptomatic therapy. Prednisolone and azathioprine represent first choice drugs, whereas several second-choice options are recommended and being considered. The marketed products for the treatment of Myasthenia Gravis include Eculizumab (Alexion Pharmaceuticals); Tacrolimus (Astellas Pharma) and others. Some of the key players involved in the development of the therapeutics for the treatment of Myasthenia Gravis include Akari Therapeutics, Alpha Cancer Technologies, AnTolRx, Argenx among others. 

Myasthenia Gravis Pipeline Analysis

Report Segmentation

Products covered by Phase

  • Phase III
  • Phase II
  • Phase I
  • Pre-clinical
  • Discovery
  • Dormant
  • Discontinued

Therapeutic Assessment by Stages

  • Product Type
  • Route of Administration
  • Molecule Type

Top Companies Analyzed

  • Akari Therapeutics
  • Alpha Cancer Technologies
  • AnTolRx
  • Argenx
  • Catalyst Pharmaceuticals
  • CSL Behring
  • CuraVac
  • Grifols Therapeutics
  • GT Biopharma
  • Hibernaid
  • Immunovant (Roivant Sciences)
  • Momenta Pharmaceuticals
  • Novartis
  • Protalex
  • Ra Pharmaceuticals
  • Toleranzia
  • Tolerion
  • UCB Pharma